Reproterol

• Description:

  Reproterol is a dual acting β2-adrenoceptor agonist and PDE inhibitor. The theophylline constituent of Reproterol inhibits phosphodiesterase activity induced by adenylyl cyclase. Reproterol has the potential for asthma research[1][2].

• UNSPSC:

  12352005

• Target:

  Adrenergic Receptor; Phosphodiesterase (PDE)

• Type:

  Reference compound

• Related Pathways:

  GPCR/G Protein; Metabolic Enzyme/Protease; Neuronal Signaling

• Applications:

  COVID-19-immunoregulation

• Field of Research:

  Inflammation/Immunology

• Assay Protocol:

  https://www.medchemexpress.com/reproterol.html

• Purity:

  96.62

• Solubility:

  DMSO : 3.9 mg/mL (ultrasonic; warming)

• Smiles:

  O=C(N1C)N(C)C2=C(N(CCCNCC(C3=CC(O)=CC(O)=C3)O)C=N2)C1=O

• Molecular Formula:

  C18H23N5O5

• Molecular Weight:

  389.41

• References & Citations:

  [1]Uwe R Juergens, et al. Different mechanisms of action of beta2-adrenergic receptor agonists: a comparison of reproterol, fenoterol and salbutamol on monocyte cyclic-AMP and leukotriene B4 production in vitro. Eur J Med Res. 2004 Jul 30;9 (7) :365-70.|[2]C G Georgakopoulos, et al. Excretion study of the beta2-agonist reproterol in human urine. J Chromatogr B Biomed Sci Appl. 1999 Apr 16;726 (1-2) :141-8.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category:

  Reference compound1

• Clinical Information:

  Phase 2

• Isoform:

  β adrenergic receptor

• CAS Number:

  [54063-54-6]